S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
China July exports rise, with trade surplus at record-high
pixel
Demand for grocery delivery cools as food costs rise
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
pixel
Shift in war's front seen as ships cleared to leave Ukraine
Transit woes mount for Boston's beleaguered subway riders
Dems push Biden climate, health priorities toward Senate OK
pixel
NASDAQ:FOLD

Amicus Therapeutics (FOLD) Stock Forecast, Price & News

$12.18
+1.24 (+11.33%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.64
$12.69
50-Day Range
$7.62
$12.18
52-Week Range
$5.91
$12.69
Volume
6.40 million shs
Average Volume
2.89 million shs
Market Capitalization
$3.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.25

Amicus Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
25.2% Upside
$15.25 Price Target
Short Interest
Healthy
7.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.04mentions of Amicus Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$1.24 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.88) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

362nd out of 1,283 stocks

Pharmaceutical Preparations Industry

156th out of 615 stocks

Amicus Therapeutics logo

About Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group assumed coverage on shares of Amicus Therapeutics in a report on Wednesday, April 13th. They issued a "neutral" rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $15.25.

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD opened at $12.18 on Friday. The firm's 50 day moving average price is $9.95 and its 200-day moving average price is $9.01. Amicus Therapeutics has a 52-week low of $5.91 and a 52-week high of $12.69. The company has a current ratio of 4.00, a quick ratio of 3.81 and a debt-to-equity ratio of 1.63.

Amicus Therapeutics (NASDAQ:FOLD - Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02. Amicus Therapeutics had a negative net margin of 87.50% and a negative return on equity of 91.37%. During the same period in the prior year, the firm earned ($0.19) EPS. On average, research analysts forecast that Amicus Therapeutics will post -0.88 earnings per share for the current year.

Insider Activity at Amicus Therapeutics

In related news, CEO John F. Crowley sold 11,346 shares of the stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $8.00, for a total transaction of $90,768.00. Following the transaction, the chief executive officer now owns 932,807 shares in the company, valued at $7,462,456. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO John F. Crowley sold 11,346 shares of the stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $8.00, for a total transaction of $90,768.00. Following the transaction, the chief executive officer now owns 932,807 shares in the company, valued at $7,462,456. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Ellen Rosenberg sold 11,122 shares of the stock in a transaction that occurred on Tuesday, June 21st. The shares were sold at an average price of $10.00, for a total transaction of $111,220.00. Following the transaction, the insider now owns 291,830 shares in the company, valued at approximately $2,918,300. The disclosure for this sale can be found here. Insiders have sold a total of 130,779 shares of company stock worth $1,237,966 over the last quarter. Company insiders own 2.50% of the company's stock.

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Stock News Headlines

See More Headlines

Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FOLD Company Calendar

Last Earnings
8/04/2022
Today
8/07/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:FOLD
CUSIP
03152W10
Employees
496
Year Founded
2002

Price Target and Rating

Average Stock Price Forecast
$15.25
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+25.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-250,460,000.00
Pretax Margin
-81.47%

Debt

Sales & Book Value

Annual Sales
$305.51 million
Book Value
$1.10 per share

Miscellaneous

Free Float
273,159,000
Market Cap
$3.41 billion
Optionable
Optionable
Beta
0.96

Social Links















FOLD Stock - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amicus Therapeutics stock.
View analyst ratings for Amicus Therapeutics
or view top-rated stocks.

What is Amicus Therapeutics' stock price forecast for 2022?

5 Wall Street analysts have issued 1 year target prices for Amicus Therapeutics' shares. Their FOLD stock forecasts range from $14.00 to $16.00. On average, they predict Amicus Therapeutics' share price to reach $15.25 in the next year. This suggests a possible upside of 25.2% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Amicus Therapeutics' stock performed in 2022?

Amicus Therapeutics' stock was trading at $11.55 at the beginning of 2022. Since then, FOLD shares have increased by 5.5% and is now trading at $12.18.
View the best growth stocks for 2022 here
.

Are investors shorting Amicus Therapeutics?

Amicus Therapeutics saw a decline in short interest in July. As of July 15th, there was short interest totaling 21,750,000 shares, a decline of 18.5% from the June 30th total of 26,700,000 shares. Based on an average trading volume of 3,850,000 shares, the short-interest ratio is presently 5.6 days.
View Amicus Therapeutics' Short Interest
.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our earnings forecast for Amicus Therapeutics
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) announced its quarterly earnings data on Thursday, August, 4th. The biopharmaceutical company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. Amicus Therapeutics had a negative net margin of 87.50% and a negative trailing twelve-month return on equity of 91.37%. During the same period in the prior year, the firm posted ($0.19) EPS.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $350.00 million-$365.00 million, compared to the consensus revenue estimate of $355.01 million.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Candriam S.C.A. (0.30%), Peregrine Capital Management LLC (0.28%), Integral Health Asset Management LLC (0.25%), DekaBank Deutsche Girozentrale (0.08%), Transcend Capital Advisors LLC (0.07%) and Mirae Asset Global Investments Co. Ltd. (0.06%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics
.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $12.18.

How much money does Amicus Therapeutics make?

Amicus Therapeutics (NASDAQ:FOLD) has a market capitalization of $3.41 billion and generates $305.51 million in revenue each year. The biopharmaceutical company earns $-250,460,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 496 workers across the globe.

When was Amicus Therapeutics founded?

Amicus Therapeutics was founded in 2002.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The official website for Amicus Therapeutics is www.amicusrx.com. The biopharmaceutical company can be reached via phone at (215) 921-7600, via email at afaughnan@amicusrx.com, or via fax at 609-662-2001.

This page (NASDAQ:FOLD) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.